Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma:A MASK-air study

Introduction Adherence to controller medication is a major problem in asthma management, being difficult to assess and tackle. mHealth apps can be used to assess adherence. We aimed to assess the adherence to inhaled corticosteroids+long-acting β2-agonists (ICS+LABA) in users of the MASK-air® app, comparing the adherence to ICS+formoterol (ICS+F) with that to ICS+other LABA. Materials and methods We analysed complete weeks of MASK-air® data (2015-2022; 27 countries) from patients with self-reported asthma and ICS+LABA use. We compared patients reporting ICS+F versus ICS+other LABA on adherence levels, symptoms and symptom-medication scores. We built regression models to assess whether adherence to ICS+LABA was associated with asthma control or short-acting beta-agonist (SABA) use. Sensitivity analyses were performed considering the weeks with no more than one missing day. Results In 2598 ICS+LABA users, 621 (23.9%) reported 4824 complete weeks and 866 (33.3%) reported weeks with at most one missing day. Higher adherence (use of medication ≥80% of weekly days) was observed for ICS+other LABA (75.1%) when compared to ICS+F (59.3%), despite both groups displaying similar asthma control and work productivity. The ICS+other LABA group was associated with more days of SABA use than the ICS+F group (median=71.4% versus 57.1% days). Each additional weekly day of ICS+F use was associated with a 4.1% less risk in weekly SABA use (95%CI=-6.5;-1.6%;p=0.001). For ICS+other LABA, the percentage was 8.2 (95%CI=-11.6;-5.0%;p<0.001). Conclusions In asthma patients adherent to the MASK-air app, adherence to ICS+LABA was high. ICS+F users reported lower adherence but also a lower SABA use and a similar level of control

Digitally‐Enabled, Patient‐Centred Care in Rhinitis and Asthma Multimorbidity: The ARIA‐MASK‐air ® Approach

MASK-air® , a validated mHealth app (Medical Device regulation Class IIa) has enabled large observational implementation studies in over 58,000 people with allergic rhinitis and/or asthma. It can help to address unmet patient needs in rhinitis and asthma care. MASK-air® is a Good Practice of DG Santé on digitally-enabled, patient-centred care. It is also a candidate Good Practice of OECD (Organisation for Economic Co-operation and Development). MASK-air® data has enabled novel phenotype discovery and characterisation, as well as novel insights into the management of allergic rhinitis. MASK-air® data show that most rhinitis patients (i) are not adherent and do not follow guidelines, (ii) use as-needed treatment, (iii) do not take medication when they are well, (iv) increase their treatment based on symptoms and (v) do not use the recommended treatment. The data also show that control (symptoms, work productivity, educational performance) is not always improved by medications. A combined symptom-medication score (ARIA-EAACI-CSMS) has been validated for clinical practice and trials. The implications of the novel MASK-air® results should lead to change management in rhinitis and asthma.info:eu-repo/semantics/publishedVersio

The ARIA-MASK-air® approach

Funding Information: The authors thank Ms Véronique Pretschner for submitting the paper. MASK‐air has been supported by Charité Universitätsmedizin Berlin, EU grants (EU Structural and Development Funds Languedoc Roussillon and Region PACA; POLLAR: EIT Health; Twinning: EIP on AHA; Twinning DHE: H2020; Catalyse: Horizon Europe) and educational grants from Mylan‐Viatris, ALK, GSK, Novartis, Stallergènes‐Greer and Uriach. None for the study. ® Publisher Copyright: © 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.MASK-air®, a validated mHealth app (Medical Device regulation Class IIa) has enabled large observational implementation studies in over 58,000 people with allergic rhinitis and/or asthma. It can help to address unmet patient needs in rhinitis and asthma care. MASK-air® is a Good Practice of DG Santé on digitally-enabled, patient-centred care. It is also a candidate Good Practice of OECD (Organisation for Economic Co-operation and Development). MASK-air® data has enabled novel phenotype discovery and characterisation, as well as novel insights into the management of allergic rhinitis. MASK-air® data show that most rhinitis patients (i) are not adherent and do not follow guidelines, (ii) use as-needed treatment, (iii) do not take medication when they are well, (iv) increase their treatment based on symptoms and (v) do not use the recommended treatment. The data also show that control (symptoms, work productivity, educational performance) is not always improved by medications. A combined symptom-medication score (ARIA-EAACI-CSMS) has been validated for clinical practice and trials. The implications of the novel MASK-air® results should lead to change management in rhinitis and asthma.publishersversionpublishe

Rhinitis associated with asthma is distinct from rhinitis alone: TARIA‐MeDALL hypothesis

Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of “one-airway-one-disease,” coined over 20 years ago, is a simplistic approach of the links between upper- and lower-airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitization and multimorbidity, (iii) advances in mHealth for novel phenotype definitions, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper- and lower-airway allergic diseases with skin, gut, and neuropsychiatric multimorbidities, is the “Epithelial Barrier Hypothesis.” This review determined that the “one-airway-one-disease” concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme “allergic” (asthma) phenotype combining asthma, rhinitis, and conjunctivitis.info:eu-repo/semantics/publishedVersio

Proline metabolism as regulatory hub

Proline is a multifunctional amino acid that is accumulated in high concentrations in plants under various stress conditions. Proline accumulation is intimately connected to many cellular processes, such as osmotic pressure, energy status, nutrient availability, changes in redox balance, and defenses against pathogens. Proline biosynthesis and catabolism is linked to photosynthesis and mitochondrial respiration, respectively. Proline can function as a signal, modulating gene expression and certain metabolic processes. We review important findings on proline metabolism and function of the last decade, giving a more informative picture about the function of this unusual amino acid in maintaining cellular homeostasis, modulating plant development, and promoting stress acclimation. © 2021 Elsevier Lt

La virescence de l'hortensia. II - Recherche d'une methode de diagnostic en microscopie de fluorescence et reperage en lumiere normale et en contraste de phases des zones suspectes sur les echantillons inclus dans les resines

International audienceWe have investigated the mild virescence disease of Hydrangea macrophylla by the use of the fluorochrome bisbenzimid H, Hoechst reagent 33258. In the sieve tubes of virescent plants, brilliant white-blue fluorescence was observed under ultra-violet light. In the corresponding parts of normal plants no such fluorescence could be detected. Blue and ultra-violet light gave complementary information. Sections were observed unstained and stained with the fluorochrome for comparative studies. Abnormal sieve tubes in unstained preparations manifested diffused primary fluorescence. The fluorochrome showed bright fluorescence indicating the presence of DNA-containing structures in the diseased sieve tubes. When the sieve tubes were not fully packed with these structures, epifluorescence resolved them as isolated granules. In order to select the suitable areas in resinembedded samples, thionin-acridine orange staining was found desirable. In 1.0 μm thick sections, the infected sieve tubes and the structures contained in them were stained blue-green with thionin. Acridine orange gave better contrast between the cell-wall and inner contents.Pour la détection des maladies à MLO, une méthode de microscopie photonique accessible à différents laboratoires est nécessaire. Le diagnostic de ces maladies est rendu plus précis et plus simple grâce à l’utilisation de la microscopie de fluorescence et des fluorochromes spécifiques de l’ADN. Le travail mentionné ici concerne la détection de la virescence de l’hortensia (Hydrangea macrophylla) grâce à l’utilisation d’un fluorochrome : le réactif de Hoechst (bisbenzimid H réactif 33258). Une fluorescence brillante, bleu clair, est observée en lumière ultra-violette dans les tubes criblés infectés des plantes virescentes. Les zones correspondantes des plantes saines en sont dépourvues. Les observations en lumière bleue et ultraviolette se montrent complémentaires. La fluorescence secondaire, en présence du fluorochrome, a constamment été comparée à la fluorescence primaire (autofluorescence) en l’absence de tout colorant. Le fluorochrome agit spécifiquement sur les particules contenant de l’ADN dans les tubes criblés infectés. La fluorescence primaire correspondante apparaît moins intense. Lors de l’observation de particules à l’état isolé, la fluorescence en lumière réfléchie (épifluorescence) s’avère supérieure à la fluorescence en lumière transmise. Afin de repérer les zones infectées à partir d’échantillons inclus dans la résine, l’utilisation de la coloration de coupes semi-fines de 1 μm d’épaisseur par la thionine et l’acridine orange se révèle intéressante. La thionine colore en bleu vert les tubes criblés infectés. Des particules isolées ont pu être observées. L’acridine orange, en augmentant le contraste entre les parois et le contenu des tubes criblés, contribue à faciliter le repérage des zones infectées

La virescence de l’hortensia. I. - Description de la maladie et transmission par Cuscuta subinclusa à un hôte différentiel, Catharanthus roseus

International audienceA virescence disease has recently been observed in France on Hydrangea macrophylla. This ornamental plant is cultivated in a rather particular way, comprising two successive phases : "production of mature plants" and "production of flowering plants". The possible period of disease inception and symptom appearance has been studied with respect of these two phases. Symptoms have been compared with those already described from different localities in Europe and America. Transmission of the pathogen to the differential host periwinkle (Catharanthus roseus) through dodder (Cuscuta subinclusa) revealed that the virescence observed in France was different from that in Belgium and had some similarities with the grassy shoot disease of Gladiolus.Les symptômes de la virescence de l’hortensia récemment apparue en France sont comparés à ceux décrits dans divers pays d’Europe et aux U.S.A. Leur période d’apparition et les risques de contamination sont décrits en tenant compte de la culture particulière de l’hortensia, caractérisée par deux stades très différents : la culture « en vert » et le « forçage ». La transmission à Catharanthus roseus par Cuscuta subinclusa montre que la souche observée en France diffère de celle décrite en Belgique et présente de grandes analogies avec les germes fins ou Aster Yellow du glaïeul

L'identification des différentes espèces du genre Cedrus à l'aide de marqueurs moléculaires AFLP

National audienc

LIGNOGUIDE : Guide d’aide au choix des cultures lignocellulosiques

LIGNOGUIDE : Guide d’aide au choix des cultures lignocellulosique

Characterization and classification of plant cyclin sequences related to A-and B-type cyclins

*INRA Laboratoire de Biochimie et Physiologie Végétale, Montpellier 34060 Diffusion du document : INRA Laboratoire de Biochimie et Physiologie Végétale, Montpellier 34060International audienc